Cargando…

Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate (S1P). Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quanti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ottenlinger, Florian M., Mayer, Christoph A., Ferreirós, Nerea, Schreiber, Yannick, Schwiebs, Anja, Schmidt, Katrin G., Ackermann, Hanns, Pfeilschifter, Josef M., Radeke, Heinfried H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2016
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093125/ https://www.ncbi.nlm.nih.gov/pubmed/27857690 http://dx.doi.org/10.3389/fphar.2016.00412

Ejemplares similares

Activation-Induced Cell Death of Dendritic Cells Is Dependent on Sphingosine Kinase 1
por: Schwiebs, Anja, et al.
Publicado: (2016)

Nuclear Translocation of SGPP-1 and Decrease of SGPL-1 Activity Contribute to Sphingolipid Rheostat Regulation of Inflammatory Dendritic Cells
por: Schwiebs, Anja, et al.
Publicado: (2017)

Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study
por: Schmidt, Katrin G., et al.
Publicado: (2017)

Tissue Cytokine IL-33 Modulates the Cytotoxic CD8 T Lymphocyte Activity During Nutrient Deprivation by Regulation of Lineage-Specific Differentiation Programs
por: Dreis, Caroline, et al.
Publicado: (2019)

Beta adrenoceptor blockade ameliorates impaired glucose tolerance and alterations of the cerebral ceramide metabolism in an experimental model of ischemic stroke
por: Luger, Sebastian, et al.
Publicado: (2018)

Inflammation-Induced Mucosal KYNU Expression Identifies Human Ileal Crohn’s Disease
por: Huhn, Meik, et al.
Publicado: (2020)

S1P Lyase Regulates Intestinal Stem Cell Quiescence via Ki-67 and FOXO3
por: Schwiebs, Anja, et al.
Publicado: (2021)

Betulin - a plant-derived cytostatic drug - enhances antitumor immune response
por: Pfarr, Kathrin, et al.
Publicado: (2014)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2019)

PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
por: Killestein, J., et al.
Publicado: (2014)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Serum sphingolipidomic analyses reveal an upregulation of C16- ceramide and sphingosine-1-phosphate in hepatocellular carcinoma
por: Grammatikos, Georgios, et al.
Publicado: (2016)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Simultaneous and Dose Dependent Melanoma Cytotoxic and Immune Stimulatory Activity of Betulin
por: Pfarr, Kathrin, et al.
Publicado: (2015)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Alterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor Fluoxetine
por: Brunkhorst, R., et al.
Publicado: (2015)

Vitamin D Supplementation Enhances C18(dihydro)ceramide Levels in Type 2 Diabetes Patients
por: Koch, Alexander, et al.
Publicado: (2017)

Enhanced CXCR4 Expression of Human CD8(Low) T Lymphocytes Is Driven by S1P(4)
por: Burkard, Tobias, et al.
Publicado: (2021)

Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels
por: Grammatikos, Georgios, et al.
Publicado: (2016)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Low Serum Levels of (Dihydro-)Ceramides Reflect Liver Graft Dysfunction in a Real-World Cohort of Patients Post Liver Transplantation
por: Mücke, Victoria Therese, et al.
Publicado: (2018)

Second line use of Fingolimod is as effective as Natalizumab in a German out-patient RRMS-cohort
por: Braune, Stefan, et al.
Publicado: (2013)

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients
por: Leurs, Cyra E, et al.
Publicado: (2017)

Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis
por: Grahl, S., et al.
Publicado: (2021)

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
por: Sinnecker, Tim, et al.
Publicado: (2016)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Botanical Therapeutics: Phytochemical Screening and Biological Assessment of Chamomile, Parsley and Celery Extracts against A375 Human Melanoma and Dendritic Cells
por: Danciu, Corina, et al.
Publicado: (2018)

Fingolimod for the treatment of neurological diseases—state of play and future perspectives
por: Brunkhorst, Robert, et al.
Publicado: (2014)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
por: Lefort, M., et al.
Publicado: (2022)

Defective IL-23/IL-17 Axis Protects p47phox−/− Mice from Colon Cancer
por: Richter, Cornelia, et al.
Publicado: (2017)

Fingolimod Affects Transcription of Genes Encoding Enzymes of Ceramide Metabolism in Animal Model of Alzheimer’s Disease
por: Jęśko, Henryk, et al.
Publicado: (2020)

Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
por: Jamroz-Wiśniewska, Anna, et al.
Publicado: (2021)

A Sphingosine 1-Phosphate Gradient Is Linked to the Cerebral Recruitment of T Helper and Regulatory T Helper Cells during Acute Ischemic Stroke
por: Lucaciu, Alexandra, et al.
Publicado: (2020)

A Comprehensive Assessment of Apigenin as an Antiproliferative, Proapoptotic, Antiangiogenic and Immunomodulatory Phytocompound
por: Ghițu, Alexandra, et al.
Publicado: (2019)

Differential expression of CD8 defines phenotypically distinct cytotoxic T cells in cancer and multiple sclerosis
por: Burkard, Tobias, et al.
Publicado: (2022)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tikm61va7fjadltfcqpurlj9vh